The effects of a high dose, short course of interferon on hepatitis C

Journal of Gastroenterology and Hepatology (Australia)

Volumn 14, Issue 1, 1999, Pages 85-89

  Nomura, Hideyuki ^a   Tsuchiya, Yoshihiro ^b   Maruyama, Toshihiro ^b   Miki, Kouichiro ^c   Yokota, Tsutomu ^c   Okubo, Hideo ^d  

^a Shin Kokura Hospital   (Japan)

^b Kita Kyushu Polytechnics College   (Japan)

^c Center for Gastroenterology and Liver Disease   (Japan)

^d Department of Internal Medicine Kita Kyushu Municipal Tobata Hospital ^*

Author keywords

Chronic hepatitis C; Hepatitis C virus RNA; High dose; Interferon ; Short course

Indexed keywords

ALPHA INTERFERON; OIF; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HEPATITIS C; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MYALGIA; PRIORITY JOURNAL; VIRUS TYPING;

EID: 0033054036     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.1999.01801.x     Document Type: Article

References (21)

1. Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alpha: A multicenter randomized, controlled trial. N. Engl. J. Med. 1989; 321: 1501-6.
2. Di Bisceglie AM, Martin P, Kassianides C et al. Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N. Engl. J. Med. 1989; 321: 1506-10.
3. Nishiguchi S, Kuroki T, Nakatani S et al. Randomized trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-5.
4. Shindo M, Di Bisceglie AM, Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis C treated with α-interferon. Hepatology 1992; 15: 1013-16.
5. Hayashi J, Ohmiya M, Kishihara Y et al. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am. J. Gastroenterol. 1994; 89: 2151-6.
6. Falaschi P, Martocchia A, D'Urso R, Proietti A. Subacute thyroiditis during interferon-alpha therapy for chronic hepatitis C. J. Endocrinol. Invest. 1997; 20: 24-8.
7. Moriya K, Yasuda K, Koike K et al. Induction of interstitial pneumonitis during interferon treatment for chronic hepatitis C. J. Gastroenterol. 1994; 29: 514-17.
8. Makino R, Yazyu H, Kishimoto Y, Sekiya T, Hayashi K. F-SSCP: Fluorescence-based polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) analysis. PCR Meth. Applic. 1992; 2: 10.
9. Toyoda H, Fukuda Y, Koyama Y et al. Nucleotide sequence diversity of hypervariable region 1 of hepatitis C virus in Japanese hemophiliacs with chronic hepatitis C and patients with chronic post-transfusion hepatitis C. Blood 1996; 88: 1488-93.
10. Pawlotsky JM, Fleury A, Choukroun V et al. Significance of highly positive C22-3 'indeterminate' second generation hepatitis C virus (HCV) recombinant immunoblot assay (RIBA) and resolution by third generation HCV RIBA. J. Clin. Microbiol. 1994; 32: 1357-9.
11. Kato N, Yokosuka O, Hosoda K, Ito Y, Ohto M, Omata M. Quantitation of hepatitis C virus by competitive reverse transcription-polymefase chain reaction: Increase of the virus in advanced liver disease. Hepatology 1993; 18: 16-20.
12. Okamoto H, Sugiyama Y, Okada S et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources. J. Gen. Virol. 1992; 73: 673-9.
13. Simmonds P, Alberti A, Alter HJ et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19: 1321-4.
14. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
15. Okanoue T, Sakamoto S, Itoh Y et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J. Hepatol. 1996; 25: 283-91.
16. Camps J, Crisostomo S, Garcia-Granero M, Riezu-Boj JI, Civeira MP, Prieto J. Prediction of the response of chronic hepatitis C to interferon alpha: A statistical analysis of pretreatment variables. Gut 1993; 34: 1714-17.
17. Yamada G, Takatani M, Kishi F et al. Efficacy of interferon alpha therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology 1995; 22: 1351-4.
18. Hino K, Okuda M, Konishi T, Ishiko H, Okita K. Serial assay of hepatitis C virus RNA in serum for predicting response to interferon-alpha therapy. Dig. Dis. Sci. 1995; 40: 14-20.
19. Kobayashi M, Kumada H, Arase Y et al. The HCV-bDNA probe method for measurement of HCV-RNA counts by HCV genotype. Int. Hep. Comm. 1994; 2: 213-17.
20. Kato N, Sekiya H, Ootsuyama Y et al. Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. J. Virol. 1993; 67: 3923-30.
21. Kumar U, Brown J, Monjardino J, Thomas HC. Sequence variation in the large envelope glycoprotein (E2/NS1) of hepatitis C virus during chronic infection. J. Infect. Dis. 1993; 167: 726-30.